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MicroarrayIntroduction: We used an integrated molecular analysis strategy to perform class discovery on a population
of low-grade gliomas (astrocytomas, oligodendrogliomas, and mixed gliomas) to improve our understanding
of the molecular relationships among these tumors and to reconcile genotypic relationships with current
histologic and molecular strategies for tumor classiﬁcation.
Methods: Gene expression proﬁling was performed on a cross-section of World Health Organization (WHO)
grades I–II gliomas. Unsupervised class discovery algorithms identiﬁed and validated tumor clusters with
genotypic similarity, and these data were integrated with chromosomal copy number assays and RT-PCR
data to deﬁne molecular tumor subclasses. Machine learning models allowed accurate, prospective
classiﬁcation of unknown tumors into these molecular subgroups. This molecular classiﬁcation model was
compared to current histologic (WHO) and molecular pathologic (chromosome 1p and 19q deletions, p53
alterations, and Ki-67 expression) methods for glioma classiﬁcation.
Results: Molecular class discovery suggested a three-class model for low-grade gliomas. One discrete cluster
of gliomas identiﬁed the pilocytic astrocytomas, a second grouped the 1p/19q codeleted oligodendroglio-
mas, and the mixture of remaining 1p/19q intact gliomas, including astrocytomas, oligodendrogliomas, and
oligoastrocytomas, formed a third cluster with a discrete pattern of expression.
Conclusions: Integration of genomic, transcriptomic, and morphologic data for class discovery suggests a
three-class model for low-grade gliomas. Class I represents tumors with molecular similarity to pilocytic
astrocytomas, class II tumors are similar to 1p/19q codeleted oligodendrogliomas, and class III represents
inﬁltrative low-grade gliomas. This classiﬁcation is similar to current clinical paradigms for low-grade
gliomas; our work suggests a molecular basis for such models. This classiﬁcation may supplement or may
serve as the basis for a molecular pathologic alternative to current grading schemes for low-grade
gliomas and may highlight potential targets for future biologically based treatments or strategies for
future clinical trials.
© 2009 Elsevier Inc. All rights reserved.Introduction
Each year, approximately 30,000 patients are diagnosed with
central nervous system (CNS) gliomas. The majority of these tumors
are classiﬁed as high-grade (malignant) gliomas, a collective term that
encompasses anaplastic astrocytoma, anaplastic oligoastrocytoma
and anaplastic oligodendroglioma (WHO grade III tumors), as well
as gliosarcoma and glioblastoma (WHO grade IV tumors) [1].
Regardless of the histologic subtype, treatment of these patients is
similar (surgical resection + radiation ± chemotherapy) and survivalontacted at Department of
uclid Avenue, Cleveland, OH
r and Neuro-Oncology Center,
nue, Cleveland, OH 4419, USA.
ll rights reserved.is generally short (1–5 years) [2–4]. Gliomas with less malignant
histologic appearance are classiﬁed into WHO grades I–II. The
histologic classiﬁcation schema for these “low-grade gliomas” is
complex, using morphologic features, which may be inconsistent or
subject to variable interpretation, to assign tumors to several
categories, and include astrocytoma (pilocytic, pilomixoid, ﬁbrillary,
gemistocytic, protoplasmic), oligodendroglioma, mixed glioma (oli-
goastrocytoma), and subependymal giant cell astrocytoma (SEGA)
[1]. While assignment to select WHO classes (i.e., pilocytic astrocy-
toma, SEGA) has speciﬁc implications for treatment and prognosis, the
WHO class for most grades I–II gliomas does not reﬂect major
phenotypic differences. From a biological perspective, it has been
difﬁcult to determine to what degree the WHO classiﬁcation
accurately reﬂects underlying tumor cell biology.
The relative rarity of these tumors and the prolonged survival of
patients diagnosed with these lesions (5–20+ years after diagnosis)
Table 1
Demographics.
Number of patients (n) 23
Age (years) – mean 34.3
– 95% CI 4.7
Sex – M (%) 15 (65%)
– F (%) 8 (35%)
Location – supratentorial n (%) 20 (87%)
– Location – infratentorial n (%) 3 (13%)
Prior stereotactic biopsy – n (%) 5 (21%)
– n (%) GTR 12 (53%)
– n (%) NTR 6 (26%)
– n (%) STR 5 (21%)
Survival (censored, years) – Mean 3.53
– Survival (censored, years) – 95% CI 0.59
Alive at the time of analysis – n (%) 20 (87%)
CI: conﬁdence interval; GTR: gross total resection; NTR: near total resection; STR:
subtotal resection.
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low-grade gliomas, which limits large-scale, prospective trials of
treatment strategies [1]. Given sparse data, nearly all combinations of
observation, biopsy, surgical resection, and adjuvant therapy have
been advocated for management of patients with such tumors [5],
resulting in variable outcomes. A cycle develops, as multiple
treatment strategies are inconsistently applied to small subsets of
patients with low-grade gliomas, further limiting the ability to
conduct meaningful outcomes research. Accordingly, consensus
regarding optimal, biologically based management of most patients
with WHO grades I–II gliomas is lacking [5].
This problem highlights the need for a classiﬁcation system for
low-grade gliomas that reﬂects tumor biology and that can be used
prospectively to guide clinical trial design and patient management. A
molecular classiﬁcation system based upon the tumor transcriptome
is an attractive option [6,7], because phenotype is associated with
genotype. Molecular classiﬁcation using microarray expression
proﬁles has been investigated in pilocytic astrocytomas [8] and in
high-grade gliomas by ourselves [9] and others [10–16], and these
studies have identiﬁed molecular subgroups with divergent pheno-
types (including patient survival), often within a single WHO grade
[5,9]. Applying a similar approach to low-grade gliomas may identify
molecular subclasses of these tumors with prognostic and therapeutic
signiﬁcance.
Because WHO grades I–II gliomas are signiﬁcantly less common
than high-grade gliomas, availability of tissue for histologic and
molecular analysis has made such investigations more difﬁcult than
similar research for high-grade gliomas. A detailed review by Rorive
et al. [17] summarized the genomic literature for low-grade
astrocytomas to date, citing only 11 studies [12,18–27] that have
collected “sound [expression] data” [17] for these tumors. This
literature tends to be descriptive, enumerating genes that are
differentially expressed between low-grade gliomas and normal
brain [8,12,18,19,21,22,24,26,27] or between low-grade gliomas and
their high-grade counterparts [12,19–21,23–25]. While such inves-
tigations can identify genes that may be markers of malignant
progression in gliomas, these analyses have been limited in their
ability to discover novel molecular subclasses or to classify unknown
tumor samples into such classes in a prospective fashion. We believe
that an unbiased investigation of low-grade gliomas, focused on
identiﬁcation and characterization of molecular subgroups, will
further the understanding of the underlying biology of these tumors,
will stimulate continued exploration of the WHO classiﬁcation
system, and will help establish a theoretical framework in which
future attempts to correlate genotype and phenotype can be
performed.
In this study, we examine the molecular relationships among a
group of 23 tumors representing a cross-section of WHO grades I–II
gliomas. We have constructed an integrative data analysis model that
limits prospective biases, incorporates genomic, transcriptomic, and
histologic data, and facilitates unbiased class discovery based on this
integratedmolecular data. Our aim is to improve our understanding of
the relationships among these tumors and to reconcile these
relationships with current histologic and molecular strategies for
the classiﬁcation of low-grade gliomas.
Materials and methods
Inclusion criteria
Patients selected for inclusion in this study had a conﬁrmed
diagnosis of WHO grades I–II glioma (pilocytic astrocytoma, diffuse
astrocytoma, oligodendroglioma, or mixed glioma) [1]. Because of the
tendency of these tumors to affect young people, patients of any age
with the appropriate diagnosis were included. Tissue samples were
obtained during initial tumor resections performed at our institutionbetween August 2001 and August 2007 as part of standard medical
management. Patients undergoing prior stereotactic biopsy were
eligible for inclusion, but patients with prior tumor resections or prior
management with chemotherapy and/or radiotherapy were exclud-
ed. Patients were also excluded if the available clinical information
was insufﬁcient to verify study eligibility or if the pathologic specimen
was inadequate for microarray analysis.
Sample selection
This study was approved by the Cleveland Clinic Institutional
Review Board. The Brain Tumor and Neuro-Oncology Center database
was queried to generate a list of all patients meeting the inclusion
criteria. The electronic medical records of these patients were
reviewed to verify study eligibility. Dates of death were veriﬁed
using the Social Security Death Index. Tissue samples from 23 low-
grade gliomas (3 pilocytic astrocytomas, 4 grade II astrocytomas, 10
grade II oligodendrogliomas, and 6 grade II oligoastrocytomas) were
collected. All samples used in this study were immediately ﬂash
frozen at the time of resection and were subsequently stored at -80°C
until RNA extraction was performed.
Demographics
Demographic information for the 23 patients included in this study
is summarized in Table 1. The patient population was 65% male and
35% female, and the mean age of patients at the time of surgical
resection was 34.3 years (±4.66, 95% CI, range 10–60). Twenty
tumors were supratentorial (87%) and three were infratentorial
(13%). The surgical resection fromwhich tissue used in this study was
collected represented the ﬁrst surgical intervention for 18 patients
(79%), while 5 patients had undergone prior stereotactic biopsy (21%).
Twenty patients were alive at the time of analysis (87%), and a
censored survival point was entered for these patients. The mean
survival (including censored survival) was 3.53 years (±0.59, 95% CI)
from the time of diagnosis. The extent of resection in all patients was
assessed on postoperative, contrast-enhanced MRI or CT imaging.
Extent of tumor resection
We deﬁned gross total resection (GTR) as absence of residual
lesional enhancement or MRI FLAIR abnormalities, near-total resec-
tion (NTR) as trace amounts of residual enhancementwithout obvious
residual tumor mass (95–99% resection), and subtotal resection (STR)
as obvious residual tumor mass, but with resection of N88% of original
18 N.F. Marko et al. / Genomics 95 (2010) 16–24tumor. Using this deﬁnition, GTRwas achieved in 12 (53%) of patients,
NTR in 6 (26%), and STR in 5 (21%). Administration of adjuvant
therapy was highly variable after resection, which reﬂects the
variability of management protocols for patients with low-grade
gliomas and which was not controlled for in this study.
Molecular genetic data
Data from molecular genetic assays routinely performed on brain
tumor specimens at our institution were collected from the
immunohistochemistry results reported in the anatomic pathology
reports for all patients included in this study. Fluorescent in situ
hybridization (FISH) demonstrated codeletion of chromosomes 1p
and 19q in eight patients (35%), and one patient (4%) had a 19q
deletion with an intact 1p. Chromosome 1p and 19q status was not
informative in three (13%) and four (17%) patients, respectively,
consistent with no allelic imbalance. The mean Ki-67 index, a
descriptor for cellular proliferation reﬂecting the relative prevalence
of the MKI67 protein, was 4.41 (±1.48, 95% CI). TP53 immunoposi-
tivity, a marker for the presence of TP53 mutations (where 0–10%
staining represents the presence of wild-type p53 alleles and N10%
staining represents the presence of mutated p53 alleles) was wild
type in 10 patients (43%), mutated in 9 patients (39%), and was not
recorded in 4 (17%) patients.
Molecular subgroup clinical data
The clinical data for the patients whose tumors comprise each of the
identiﬁed molecular subgroups of glioma are summarized in Table 2.
These subgroups are further discussed in Results and Discussion.
Gene expression analysis
Histologic veriﬁcation of tumor cellularity and specimen quality
was performed using frozen sections of the tumor blocks stained with
hematoxylin and eosin. Gene expression analysis for the 23 tumorsTable 2
Characteristics of molecular subgroups.
Age (years) Survival (years) Histology, WHO grade Surgical out
Pilocytic astrocytoma (PA) cluster
50 4.44 Microcystic astroctyoma, grade I NTR
24 4.01 Pilocytic astrocytoma, grade I GTR
10 3.46 Pilocytic astrocytoma, grade I GTR
20 3.72 Pilocytic astrocytoma, grade I GTR
Codeleted oligodendroglioma (CO) cluster
42 2.33 Oligodendroglioma, grade II GTR
42 5.08 Oligodendroglioma, grade II NTR
27 5.18 Oligodendroglioma, grade II GTR
36 2.31 Oligodendroglioma, grade II GTR
28 1.70 Oligodendroglioma, grade II STR
36 1.83 Oligodendroglioma, grade II GTR
24 0.76 Oligodendroglioma, grade II NTR
38 6.15 Oligodendroglioma, grade II GTR
Residual low-grade gliomas
21 5.48 Astrocytoma, grade II NTR
60 2.41 Astrocytoma, grade II STR
22 2.69 Astrocytoma, grade II STR
38 3.05 Oligodendroglioma, grade II GTR
33 4.18 Oligodendroglioma, grade II GTR
32 5.59 Mixed glioma, grade II GTR
32 4.68 Mixed glioma, grade II STR
45 4.26 Mixed glioma, grade II NTR
43 3.39 Mixed glioma, grade II NTR
26 1.26 Mixed glioma, grade II GTR
37 3.17 Mixed glioma, grade II STR
GTR: gross total resection; NTR: near total resection; STR: subtotal resection;
D: deleted; I: intact; NR: not recorded.was performed following standard institutional protocols. Tissue
extraction was performed using the TriZol®method, RNAwas isolated
and puriﬁed using Qiagen® column techniques, and quantiﬁcation and
quality assurance were performed using the NanoDrop® spectropho-
tometer and the Agilent® BioAnalyzer 2100, respectively. Microarray
analysis was performed using the Affymetrix® U133 Plus 2.0 arrays
and RT-PCR [28] was performed to conﬁrm array data using the TAQ-
Man assay, both following standard protocols. Data were analyzed
using several commonly used software platforms for gene expression
analysis, and gene list annotation was performed using data from
multiple, publicly available annotation databases. Detailed descrip-
tions of these methods are available in the supplemental materials.
Results
Molecular class discovery
Characterization of differentially expressed genes in tumors vs. controls
To characterize the genes that distinguished the low-grade
gliomas group (as a whole) from normal brain, a two-sided t-test
(pb0.01) with a standard Bonferroni correction was applied to the
normalized dataset to identify a subset of 2021 genes with a high
degree of statistically signiﬁcant differential expression between
tumor and normal brain (881 overexpressed, 1140 underexpressed,
out of approximately 47,000 unique genes found on the Affymatrix
U133A plus 2.0 array; see Supplemental materials). An EASE
(Expression Analysis Systematic Explorer) [29] overrepresentation
analysis was used to identify structural, functional, and pathway
categories with statistically signiﬁcant overrepresentation in the lists
of differentially expressed genes. While the results for any speciﬁc
category are difﬁcult to interpret in isolation, this analysis gives an
overall representation of the structural and functional categories that
are differentially expressed among the tumor samples. The results of
this analysis are included in the supplemental material, including a
complete table of the identiﬁed genes (Table S1) and an abbreviated
version listing only EASE categories with 100 or more hits (Table 2).come Location 1P 19Q Ki67 (%) p53 (%)
Temporal I I 1 10
Cerebellar NR NR 2 NR
Cerebellar I NR 5 NR
Cerebellar NR NR 1 0
Frontal D D 5 0
Frontal D D 4 10
Frontal D D 3 NR
Frontal D D 3 10
Temporal D D 9 3
Temporal D D 4 0
Parietal D D 12 2
Frontal D D 2 10
Frontal NR NR 1.5 NR
Temporal I I 1 5
Frontal I I 10 50
Frontal I I 4 50
Parietal I I 10 75
Frontal I I 2 40
Frontal I I 2 50
Temporal–parietal–occipital I I 1 75
Temporal I D 12 40
Temporal I I 5 50
Frontal I I 2 50
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Genes that are differentially expressed between the tumor and
control populations serve as the basis for class discovery, while genes
without statistically-signiﬁcant differential expression do not make
meaningful contributions to class discrimination and contribute only
noise to clustering algorithms. Accordingly, a one class SAM
(signiﬁcance analysis for microarrays) [30] analysis (false discovery
rate set to 0) was used to test the log2 FITumorFIAverageControl
 
for each gene
against zero, identifying a subset of 19,876 genes with differential
expression in the tumors relative to the control. This set of genes was
used as the feature set for class discovery and clustering.Molecular relationships among low-grade gliomas
Unsupervised analysis algorithms employ unbiased searches for
patterns of expression that can be used to develop hypotheses
regarding the mechanistic associations between genotype and
phenotype. These approaches are useful to identify expression
patterns within the set of differentially expressed genes that may
have phenotypic signiﬁcance. Hierarchical clustering [31] (Fig. 1)
identiﬁed a cluster of four tumors that segregated at the most
proximal level. Comparison to histopathologic diagnosis demonstrat-
ed that this cluster included all three pilocytic astrocytomas (PA) and
one grade II astrocytoma (1p/19q intact). This fourth tumor was
classiﬁed as grade II at the time of initial resection and pathologic
review, but repeat histologic evaluation by our neuropathologist (RP)
revealed a predominantly microcystic pattern; reanalysis conﬁrmed
that this lesion was a WHO grade I astrocytoma rather than its
original, clinical pathology designation as a grade II, inﬁltrating
glioma. Moreover, this patient's clinical course has more closely
approximated that of a typical patient with a grade I glioma: the
patient is alive 5 years after a near total resection and has no clinical or
radiographic evidence of recurrence or progression. These ﬁnding
lead us to conclude that the initial, histologic classiﬁcation of this
lesion as WHO grade II was erroneous and, in fact, this was a grade I
astrocytoma. Proper reclassiﬁcation was triggered by analysis of the
microarray results. The PA cluster therefore comprises all four study
patients with WHO grade I lesions.
A second, distinct cluster of eight tumors was identiﬁed during
unbiased searching, which were found to be all oligodendrogliomas
by histology. Comparison to chromosomal copy number dataFig. 1. Hierarchical clustering with support values. Red: PA cluster (Class I); blue: CO
cluster (Class II); green: residual cluster (Class III). Numbers in grey boxes represent
percent support for each node by the Support tree algorithm (Bootstrapping).demonstrated that this cluster include eight of eight samples in the
dataset with codeletion of chromosome 1p and 19q. The support tree
algorithm [32] indicated 93% support for the pilocytic astrocytoma-
like cluster (PA) and 95% support for the codeleted oligodendro-
glioma-like cluster (CO) (Fig. 1). Analysis of principal components
[33] (Fig. 2A) and correspondence analysis [34,35] (Fig. 2B) were used
to explore these relationships. These analyses revealed that the PA
cluster segregated distinctly from the remainder of the tumors along
both the ﬁrst and the second principal components. The CO subset
also clustered discretely along the ﬁrst principal component. The
remaining tumors, which represented a mixture of grade II astrocy-
tomas, grade II mixed gliomas, and grade II oligodendrogliomas (1p/
19q intact), formed a residual cluster whose members were
distributed throughout the expression space and generally occupied
the area at the margin of the CO cluster. This relationship was
conﬁrmed with terrain mapping [36] (with neighbors=3, Fig. 3).Characteristics of the identiﬁed molecular subgroups
PA cluster
The ﬁrst molecular subgroup consisted of all four tumors identiﬁed
as WHO grade I astroctyomas. The mean age of patients in this group
was 26.0 years and the mean (censored) survival was 3.91 years,
neither of which was signiﬁcantly different from the corresponding
values for the remaining groups (Table 2).
A two-group SAM analysis was used to determine the genes that
were differentially expressed in this cluster versus the remainingFig. 2. Sample clustering by dimensional reduction. (A) Principal components analysis.
(B) Correspondence analysis. Blue: CO cluster; red: PA cluster; green: residual cluster.
Fig. 3. Terrain mapping. Blue: CO cluster; red: PA cluster; green: residual cluster.
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molecular class. A total of 1367 genes with differential expression in
this group were identiﬁed, with 1056 overexpressed in this group and
311 underexpressed relative to the remaining sample population.
Chromosomal locus and functional category overrepresentation
analysis was performed on these gene sets using EASE. The results
demonstrate overexpression of genes localizing to chromosomes 5q,
7q, 8p, 11q, and 12 and underexpression of genes on chromosome 9q
(Table 3). The results of the EASE overrepresentation analysis for
these gene lists are included in the supplemental material (Table S3).
CO cluster
The second molecular subgroup consisted of eight tumors
classiﬁed histologically as grade II oligodendrogliomas. Analysis of
the molecular genetic data for these tumors demonstrated that this
cluster represented 100% of the low-grade gliomas with chromosome
1p/19q codeletion. All eight of these tumors were supratentorial. The
mean age of patients in this group was 34.1 years and the mean
(censored) survival was 3.17 years, neither of which was signiﬁcantlyTable 3
Chromosomal overrepresentation analysis of molecular subgroups.
Category Genes EASE score
PA cluster, overrepresentation
Chromosome 12 70 4.79E-10
Chromosome 12p 22 1.31E-04
Chromosome 12q 48 2.06E-06
Chromosome 8 30 0.035
Chromosome 8p 17 0.004
Chromosome 11 51 0.006
Chromosome 11q 34 0.024
Chromosome 7 39 0.026
Chromosome 7q 29 0.016
Chromosome 5 39 0.023
Chromosome 5q 34 0.018
PA cluster, underrepresentation
Homo sapiens 9q 10 0.039
CO cluster, overrepresentation
NONE
CO cluster, underexpression
Chromosome 1 133 1.92E-44
Chromosome 1p 115 1.44E-59
Chromosome 19q 24 0.009different from the corresponding values for the remaining groups
(Table 2).
A two-group SAM analysis was used to determine the genes that
were differentially expressed in this cluster versus the remaining
tumor population. A total of 681 genes with differential expression in
this group were identiﬁed, with 161 overexpressed and 520 under-
expressed relative to the other 17 tumors. Chromosomal locus and
functional category overrepresentation analysis revealed no chromo-
some-speciﬁc overrepresentation; there was underrepresentation of
genes localizing to chromosomes 1p and 19q (pb1.44×10-59 and
pb0.009, Table 3). The EASE overrepresentation analysis is included in
the supplemental material (Table S4).
Genes that distinguish between molecular subgroups
Identiﬁcation and characterization of the PA and CO clusters gives
rise to a three-class model of low-grade gliomas. Class I represents
tumors in the PA cluster, class II corresponds to tumors in the CO
cluster, and class III is a residual cluster containing the remaining
tumor samples. Genes with distinct patterns of expression between
each of these three molecular subgroups were identiﬁed using a
three-class, one-way analysis of variance (ANOVA) with pb0.01 and a
standard Bonferroni correction. This set of 304 genes was subse-
quently characterized with EASE overrepresentation analysis. Both
the gene list and the EASE overrepresentation analysis are included in
the supplemental material (Tables S5 and S7).
Prospective classiﬁcation using machine learning models
Overview
Data sets where elements are members of known classes and
where a large set of features is associated with each element can be
used in conjunction with machine learning models to train prospec-
tive classiﬁers for novel elements having similar feature sets. Our
unbiased class discovery strategy identiﬁed three distinct classes, and
this knowledge was added to the expression data set and used to train
mathematical learningmodels capable of classifying unknown tumors
into one of these three classes based upon the expression proﬁle. To
build these models, we constructed a training set of two samples from
the PA cluster, ﬁve samples from the CO cluster, and eight samples
from the residual cluster to serve as a training set for subsequent
classiﬁers. The remaining samples comprised the test set, consisting of
two samples known to belong to the PA cluster, three from the CO
cluster, and three from the residual cluster. Speciﬁc assignments to
the training and test set were made at random.
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Machine learning models represent a robust method of prospec-
tive classiﬁcation, but the classiﬁcation results can be affected by
biases in the dataset. We used two strategies to control such potential
bias. First, while knowledge of the groupmembership of the elements
in the training set is used to train the classiﬁer, information regarding
the group assignment of elements in the test set is not introduced into
the validation process and is examined only retrospectively after
classiﬁcation of the validation set. Next, feature reduction is
performed on the complete expression data set using only variance
ﬁltering [37]. A variance ﬁlter was therefore applied to the complete,
normalized expression dataset (54,676 genes) such that the least
variable 30% (16,403) of genes were removed. This allows classiﬁca-
tion to be performed using those features most likely to facilitate
classiﬁcation [37], reduces noise in the algorithms, and does so in an
unbiased fashion.
Classiﬁcation of unknown samples by machine learning
Three machine learning models were trained and tested for
prospective classiﬁcation of low-grade gliomas. Discriminant analysis
(DA) [38] is a multistep algorithm that ﬁrst applies an ANOVA analysis
on the dataset to select genes that should be near optimal for
partitioning the unknown samples based upon permutations of gene
expression in the training set. Next, amultivariate partial least squares
(MPLS) method is used for gene dimensional reduction. This is
followed by a polychotomous discriminant analysis (PDA). The
training data were used to construct a DA classiﬁer, and validation
with the test set demonstrated classiﬁcation of the unknown samples
into the appropriate molecular classes with 100% accuracy. The list of
1049 genes and the EASE overrepresentation analysis of this list is
included in the supplemental material (Tables S5 and S6).
A second strategy for classiﬁcation is the recently described,
uncorrelated shrunken centroids (USC) model [39]. This method was
designed to allow prediction of phenotypic category of a tissue sample
based upon its expression proﬁle as well as identiﬁcation of genes
relevant to this classiﬁcation. The USC method is based upon a
shrunken centroids algorithm but modiﬁes the approach by removing
genes with highly similar expression patterns. This algorithm exploits
the functional interdependence of genes to reduce the number of
genes used for classiﬁcation, which produces a smaller set of
important genes and improves classiﬁcation accuracy. Again, the
training set was used to train the classiﬁer, and validation with the
test set demonstrated 100% accuracy in classiﬁcation. While the USC
model performed well, its dimensional reduction strategy resulted in
the inclusion of a large number of ESTs and genes with hypothetical
products in the ﬁnal list. This can be observed when using this gene
reduction algorithm with the Affymetrix® U133 Plus 2.0 arrays, and it
explains the incomplete annotations of the USC lists in the
supplemental material.
Support vector machines (SVM) [40] are perhaps the best known
machine learning model. SVMs use known relationships between
members of a subset of elements coupled with the expression
patterns of all of the elements to create a training set of numeric
weights for each element. In a second phase, the weights are used to
assign discriminators to the elements, and a binary output results in
elements being considered either “in or out” of the groups deﬁned in
the initial training process. The pattern of weights associated with
each feature can be retained after training to give information
regarding the genes used to construct the support vectors. Because
SVMs are binary, the training and test sets must be adjusted to
accommodate the model. We therefore divided the data into two
subsets of samples, one representing the class II (the CO cluster) and
one representing the remaining two classes (including both the
residual and the PA cluster). Half of the samples in each subset (4
+8=12) were selected at random to comprise the training set, and
the other half (4+7=11) were used as the test set. Variance ﬁlteringwas used (on previously unﬁltered expression data) to select themost
variable 5000 genes (9%) across these two groups to serve as the
feature set for classiﬁcation [37]. After training, the SVM classiﬁed the
test set with 100% accuracy. A second round of SVM could
theoretically be used to distinguish tumors in the PA class from the
remainder of the data set (the implementation of a binary classiﬁer in
a multiclass model), but the small number of PAs precluded adequate
training of a second round of SVM. The 2630 genes whose training
weights favored the CO class and the 2370 weighted against the CO
class, as well as the EASE overrepresentation analysis of these gene
sets, are included in the supplemental material (Tables S6 and S7).
Verifying expression data
Reverse transcriptase-polymerase chain reaction (RT-PCR) was
performed to validate the expression patterns in a subset of
differentially expressed genes [28]. Six housekeeping genes were
tested empirically. GAPDH was determined to be most consistent
control and was used as the reference for all subsequent RT-PCR.
Sixteen (16) genes that had been identiﬁed as having highly
statistically signiﬁcant differential expression between the three
classes using three-way ANOVA or the Student's t-test were assayed
in both controls and in all 23 samples, giving a total of 368 data points.
These data were analyzed using three separate strategies— an ANOVA
analysis, a relative analysis of gene expression across phenotypic
groups, and a semiquantative analysis of differential gene expression.
The ANOVA analysis and the analysis of the relative expression
patterns for each gene across the three phenotypic groups (PA, CO, and
the residual gliomas) were performed using the mean RT-PCR
ﬂuorescence value for each gene in each phenotypic group (normal-
ized to the GAPDH reference). A one-way, three-class ANOVA
(adjusted pb0.05) conﬁrmed statistically signiﬁcant differential
expression across the three phenotypic classes in nine genes (56.3%).
The relative order of the magnitude of differential expression for each
gene in each phenotypic group was examined and was compared to
array data analyzed in a similar fashion. This analysis demonstrated
that the relative order of gene expressionwas identical for 10 of the 16
genes (62.5%) in the array and the PCR analyses (Table S8).
A semiquantitative analysis of differential gene expression was
performed by calculating the log2(ratio) of each gene in the PCR
dataset relative to the mean the control value for the gene. Reliable
control data were available for 10 of the 16 genes. These 10 genes in
23 samples were used for the semiquantitative analysis, resulting in a
total of 230 data points. Internal controls in the RT-PCR system
indicated that 227 of these points represented reliable data, and this
dataset served as the basis for subsequent calculations. Analysis of the
expression data for each of the 10 genes across all 23 samples
demonstrated regulation in the same direction (either upregulation or
downregulation) for a total of 139 of the 227 data points assayed
(61.2%). Additionally, the RT-PCR and microarray data concurred on
the direction of regulation in at least 50% of samples for 8 of the 10
assayed genes (80%). Analysis of these data by sample demonstrated
concurrence of RT-PCR and microarray data for the direction of
regulation in a mean of 60.4% of the genes in each sample. Forty
(17.6%) of these data points demonstrated b50% difference in the
measured magnitude of differential gene expression (relative to
control), although comparisons of magnitude of differential regula-
tion across platforms are subject to multiple sources of error andmust
be interpreted cautiously (Table S9).
Discussion
Demographic and clinical data
Table 1 summarizes the demographic data for the 23 patients in
this investigation, and Table 2 presents relevant clinical data,
including patient age and survival, location and characterization of
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molecular pathologic data for each tumor. The difference in mean
survival for the three clusters does not achieve statistical signiﬁcance.
This is likely attributable to a combination of the more indolent
disease course characteristic of low-grade gliomas (N5-year survival)
and the large number of censored survival values in our cohort (87%).
Because of the potential biases associated with using censored data to
analyze time to progression, we have not reported on this clinical
parameter. Also, because management strategies for low-grade
gliomas are highly variable – both from center to center and between
patients in the same center – and because our sample size is relatively
small, we have not commented on response to therapy (see
supplemental discussion). Of note, while the sample size in this
investigation is relatively small, it represents one of the largest, most
comprehensive molecular investigations of low-grade gliomas
reported to date [12,18–27].
Integrative analytic model
For many years, our understanding of the relationships among
low-grade gliomaswas based almost entirely upon histologic features,
which are the basis of the WHO grading scheme. More recently,
molecular differences among WHO grades I–II gliomas have been
described [17,41] but the signiﬁcance of many of these ﬁndings
remains unclear. Themost promisingmolecular data to date has come
with the discovery and characterization of a subset of oligodendro-
gliomas with codeletions of chromosome 1p and 19q (principally a
translocation of 1p to 19q), a molecular marker in otherwise
histologically identical tumors that generally correlates with im-
proved response to chemotherapy and prolonged survival relative to
patients with 1p/19q intact tumors [42–44]. Findings such as thisFig. 4. Analytcontribute to the case that molecular differences among histologically
similar tumors may have phenotypic signiﬁcance [9] but limited
research into molecular relationships among low-grade gliomas has
left much uncertainty regarding the number and nature of such
molecular subclasses. The current WHO system does not include
molecular classiﬁcation data [1].
We intended to identify, in an unbiased fashion, the number and
nature of molecular subgroups that exist among WHO grades I–II
gliomas. The data analysis model we implemented is designed to
integrate data from the genomic, transcriptomic, and morphologic
domains so as to identify and characterize these molecular subgroups
(Fig. 4). Once samples of low-grade gliomas are appropriately
examined by an experienced neuropathologist (RP), molecular
analyses are blinded to histologic information to eliminate potential
bias. Preliminary class discovery is guided by unsupervised analysis of
gene expression data, but ﬁnal delineation of molecular classes is
made through an integrative analysis of chromosomal, histologic, RT-
PCR, and expression data. This structure also facilitates cross-
validation of ﬁndings from each of the platforms (Fig. 4). Once
molecular classes have been identiﬁed, this knowledge is used, along
with expression data, in an unbiased fashion, to train prospective
classiﬁers, and the classiﬁers are validated using expression proﬁles of
novel tumors that were not part of the training set. Of primary
importance in this model are the capability for intrinsic cross-
validation and the integrative data analysis involved in class
discovery.
Data cross-validation
Microarray expression data, RT-PCR data, and information on
chromosomal copy number were cross-validated as outlined in Fig. 1.ic model.
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were annotated with chromosomal localization, and an EASE
overrepresentation of this analysis demonstrated strong under-
expression of genes localized to chromosomes 1p and 19q (Table 3).
This matched the chromosomal copy number data, which demon-
strated 1p/19q codeletion in all eight members of this cluster.
Similar analysis of overexpressed genes in the PA cluster suggested
overrepresentation of genes localizing to chromosomes 5q, 7q, 8p,
11q, and 12 (Table 3), and ampliﬁcations of all of these loci have
been reported in the literature [45–50], most notably at 7q. We did
not validate each of these potential copy number variations by
whole-genome copy number analysis, but our data analysis model
would accommodate such cross-validation as part of a more
extensive study. Similarly, microarray and RT-PCR platforms were
used to cross-validate measured gene expression levels. RT-PCR was
performed on a subset of 16 genes with differential expression
demonstrated by microarray analysis, and both a relative analysis of
gene expression across phenotypic groups and a semiquantative
analysis of differential gene expression supported the ﬁndings of the
microarray analysis.Three-class model for low-grade gliomas
The result of our integrative analysis for molecular class discovery
is a three-class model for low-grade glioma classiﬁcation. Class I,
identiﬁed as the PA cluster, contains all of the samples histologically
identiﬁed as WHO grade I lesions. This cluster is well supported in all
class discovery algorithms and has gene expression signatures that
are clearly distinct from the remainder of the low-grade gliomas. This
subclassiﬁcation is also consistent with general clinical characteristics
of pilocytic astrocytomas, which, unlike other low-grade gliomas,
tend to be circumscribed and noninﬁltrative and are uniformly cured
with gross total resection.
Class II, the CO cluster, represents a subset of low-grade gliomas
found to have codeletion of chromosomes 1p and 19q by copy number
analysis. This pattern of deletion is well described in the current
literature [42–44]. By the WHO system, all of the tumors in this
cluster, as well as two tumors in the residual cluster (class III), would
be identiﬁed as oligodendrogliomas. Clinically, oligodendrogliomas
with 1p/19q codeletion/translocations are inﬁltrative, but their
response to current standard medical therapy and therefore their
progression free survival rate is generally better than that of their 1p/
19q intact counterparts.
Class III represents tumors not included in the PA or CO cluster. The
expression patterns of these tumors are variable, and this cluster
therefore appears on PCA and COA plots a “cloud” of samples
distributed in multidimensional expression space. Clinically, this
cluster represents a group of tumors with heterogeneous histology
that are often considered as 1p/19q intact, low-grade, inﬁltrating
gliomas. In general, such tumors are prone to progression and
conversion to more malignant phenotypes. By the WHO system, this
cluster is composed of a heterogeneous mix of non-pilocytic astrocy-
tomas, some oligodendrogliomas, and mixed oligoastrocytomas.
Our model highlights potential areas for enhancing pathological
classiﬁcation nosologies for low-grade gliomas. While the WHO
system does segregate pilocytic astrocytomas as distinct, 1p/19q
deleted and 1p/19q intact oligodendrogliomas are grouped in a single
category despite their divergent clinical performance and patterns of
gene expression. Moreover, there are multiple WHO histological
categories for the remaining low-grade gliomas (astrocytoma,
oligodendroglioma, and oligoastrocytoma), which we have clustered
together into class III. These tumors have similar patterns of gene
expression and overlapping but not identical clinical behaviors. The
biological relationships between tumor genotype and clinical pheno-
type in these tumors remain to be explored.Clinical signiﬁcance
The World Health Organization (WHO) grading system for glial
tumors [1] provides at least eight classes for WHO grades I–II glial
tumors. These classes are based purely upon histology; the WHO
scheme does not use clinical or molecular data to develop these
classes. By contrast, the three-class model that we have constructed is
predicated upon molecular data from an integrated molecular
analysis, and the identiﬁed classes correlate with current clinical
paradigms regarding clinical behavior and management of low-grade
gliomas. In our model, tumors with a proﬁle similar to pilocytic
astrocytomas are assigned to class I, inﬁltrative tumors similar to 1p/
19q codeleted oligodendrogliomas are assigned to class II, and the
remaining, inﬁltrative tumors are designated as class III. These three
groups have distinct genotypes, both at the DNA and at the
transcriptomic level. Similarly, current understanding of the clinical
phenotypes of tumors assigned to these classes suggests that class I
may represent tumors that are circumscribed and curable with
resection, class II may reﬂect tumors that are inﬁltrating but respond
favorably to current therapeutic modalities, and class III may be
gliomas that may have an increased tendency toward treatment
resistance, relative to class II tumors. This correlation between the
three molecular classes and the three broad categories of clinical
performance suggest that there may be a biological basis to the
current clinical paradigm regarding the management of low-grade
gliomas that is reﬂected in the transcriptome. Additionally, our
ﬁndings suggest that molecular differences have the potential to serve
as the basis for a clinically relevant classiﬁcation scheme that may
serve as a more accurate model to determine prognosis, to guide
selection of therapeutic options, and to aid in the design of clinical
trials, especially those that are expected to act on speciﬁc molecules or
pathways. Additional information regarding potential limitations of
this study – and future directions for research based upon the ﬁndings
of this investigation – are detailed in the supplemental materials.
Conclusions
WHO grades I–II gliomas are a heterogeneous group of tumors
whose histology, patterns of gene expression, phenotypes, and
prognosis are variable. The goal of this study was to investigate, in
an unbiased fashion, the number and nature of molecular subgroups
that exist among these gliomas, and the data analysis model that we
have implemented was designed to integrate data from the genomic,
transcriptomic, and cellular levels for the purpose of identifying and
characterizing these molecular subgroups. Our investigations suggest
a three-class model for low-grade gliomas, where class I represents
tumors with molecular similarity to pilocytic astrocytomas, class II
represents gliomas with 1p/19q codeletions, and class III represents
diffuse, inﬁltrating, low-grade gliomas. We have presented robust
molecular data for our model. We believe that this classiﬁcation may
be a useful supplement to the current WHO grading scheme for low-
grade gliomas.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.ygeno.2009.09.007.
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